<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04641767</url>
  </required_header>
  <id_info>
    <org_study_id>BIOTRABIS_FMM-AP171562019</org_study_id>
    <nct_id>NCT04641767</nct_id>
  </id_info>
  <brief_title>BIOmarkers of TRAumatic Brain Injury Spain (BIOTRABIS)</brief_title>
  <acronym>BIOTRABIS</acronym>
  <official_title>&quot;Fast Heart Fatty Acid Binding Protein (H-FABP) Determination to Rule Out Brain Damage in Mild Traumatic Brain Injury (TBI): the First Multicenter Study Using a Point of Care Device at Trauma and Pediatric Emergency Departments.&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Virgen Macarena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospitales Universitarios Virgen del Rocío</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Sant Joan de Deu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Infantil Universitario Niño Jesús, Madrid, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Complejo Hospitalario La Mancha Centro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Son Espases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Miguel Servet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitario Virgen Macarena</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traumatic brain injury (TBI) is defined as a structural alteration of brain function caused&#xD;
      by external causes, where mild traumatic brain injury (mTBI) represents approximately 80% of&#xD;
      all TBI, and although its prognosis is relatively good, it represents a significant cost to&#xD;
      the system due to the need to perform a cranial computed tomography (CT) scan, a test of high&#xD;
      economic value and not without risks such as irradiation, especially important and dangerous&#xD;
      in the pediatric age.&#xD;
&#xD;
      The investigators aim to set-up a point of-care (POC) device to validate a biomarker (H-FABP)&#xD;
      able to diagnose the presence of brain damage in children and adults with mTBI at trauma and&#xD;
      paediatric Emergency Departments using a blood sample, in order to save resources and avoid&#xD;
      subjecting patients to a potentially damaging imaging test. But also, to assess whether the&#xD;
      incorporation of new biomarkers improves the prediction of brain damage that can be done with&#xD;
      H-FABP.&#xD;
&#xD;
      For that, the investigators will recruit a 400 patients' cohort with blood samples using the&#xD;
      available POC device for H-FABP biomarker.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Brain damage diagnostic accuracy</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>Brain damage diagnostic in mild TBI patients during hospital admission [% brain damage versus % non brain damage] will be determined by clinical and neuroimaging criteria (CT) at emergency departments arrivals and compared with diagnostic accuracy of a blood biomarker based test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain damage long term diagnostic accuracy</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>Brain damage diagnostic in mild TBI patients after 3 months [% brain damage long term versus % non brain damage long term ] will be determined by Glasgow Outcome Score (GOSe) through telephone call and compared with previous diagnostic accuracy of a blood biomarker based test.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Mild Traumatic Brain Injury</condition>
  <condition>Moderate Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>BIOTRABIS&gt;18 - Pathologic patients</arm_group_label>
    <description>Group that includes adult patients under study. Those with mild TBI will be recruited. In order to determine the severity of the mild TBI, the doctor uses a scale called the Glasgow GCS scale and mild TBI is understood as those with GCS: 14-15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIOTRABIS&gt;18 - Control patients</arm_group_label>
    <description>Group that includes adult control patients. Those with very mild TBI will be recruited (GCS: 15) without symptoms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIOTRABIS&lt;18 - Pathologic patients</arm_group_label>
    <description>Group of paediatric patients under study. This will recruit those who come to the emergency department with mild TBI (GCS 14-15) or moderate (GCS 9-13).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIOTRABIS&lt;18 - Control patients</arm_group_label>
    <description>Group that includes paediatric control patients. Those with very mild TBI will be recruited (GCS: 15) without symptoms</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        BIOTRABIS&gt; 18: Group that includes adult patients. Those with mild TBI will be recruited.&#xD;
        In order to determine the severity of the TBI, the doctor uses a scale called the Glasgow&#xD;
        GCS scale and mild TBI is understood as those with GCS: 14-15.&#xD;
&#xD;
        BIOTRABIS &lt;18: Group of pediatric patients. This will recruit those who come to the&#xD;
        emergency department with mild TBI (GCS 14-15) or moderate (GCS 9-13).&#xD;
&#xD;
        Each group is subdivided into pathological patients (those under study) or control&#xD;
        patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        BIOTRABIS&gt;18 (adult patients)&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 18 years old&#xD;
&#xD;
          -  Mild TBI patients the first 24 hours after trauma with GCS of 14-15 points.&#xD;
&#xD;
          -  Presence of any of the following symptoms:&#xD;
&#xD;
               -  Loss of consciousness less than 30 minutes, the first 20 minutes after trauma&#xD;
&#xD;
               -  Post-traumatic amnesia less than 24 hours, the first 30 minutes after trauma:&#xD;
&#xD;
               -  Persistent headache&#xD;
&#xD;
               -  Nausea / vomiting&#xD;
&#xD;
               -  Vertigo / dizziness&#xD;
&#xD;
               -  Confusion / disorientation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dementia or other pre-existing neurological condition that makes evaluation difficult&#xD;
&#xD;
          -  Recent history (&lt;1 month) of TBI&#xD;
&#xD;
          -  Refusal to participate in the study&#xD;
&#xD;
          -  Evidence of alcohol or other substance intoxication&#xD;
&#xD;
          -  Previous stroke&#xD;
&#xD;
          -  Previous severe TBI&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Schizophrenia&#xD;
&#xD;
          -  Neurodegenerative disease&#xD;
&#xD;
        BIOTRABIS&lt;18 (paediatric patients)&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients between 0 and 17 years old.&#xD;
&#xD;
          -  Mild TBI (GCS 14-15) and moderate TBI (GCS 9-13) patients the first 24 hours after&#xD;
             trauma.&#xD;
&#xD;
          -  Presence of any of the following symptoms:&#xD;
&#xD;
               -  Loss of consciousness less than 30 minutes, the first 20 minutes after trauma&#xD;
&#xD;
               -  Post-traumatic amnesia less than 24 hours, the first 30 minutes after trauma:&#xD;
&#xD;
               -  Persistent headache&#xD;
&#xD;
               -  Nausea / vomiting&#xD;
&#xD;
               -  Vertigo / dizziness&#xD;
&#xD;
               -  Confusion / disorientation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dementia or other pre-existing neurological condition that makes evaluation difficult&#xD;
&#xD;
          -  Recent history (&lt;1 month) of TBI&#xD;
&#xD;
          -  Refusal to participate in the study&#xD;
&#xD;
          -  Evidence of alcohol or other substance intoxication&#xD;
&#xD;
          -  Previous stroke&#xD;
&#xD;
          -  Previous severe TBI&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Schizophrenia&#xD;
&#xD;
          -  Neurodegenerative disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elvira Chocano, MSc</last_name>
    <phone>+34 93 4893000</phone>
    <phone_ext>4941</phone_ext>
    <email>elvira.chocano@vhir.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luis Sempere, PhD</last_name>
    <phone>+34 955 012 638</phone>
    <email>lluissemperebordes@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roser García, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Belén Menéndez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Méndez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan Deu Barcelona</name>
      <address>
        <city>Esplugues De Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carles Luaces, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victoria Trenchs, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario La Mancha Centro</name>
      <address>
        <city>Alcázar De San Juan</city>
        <state>Ciudad Real</state>
        <zip>13600</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ángel Luis Laguna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Mallorca</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elena Miravet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <state>Seville</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Sempere, PhD</last_name>
      <phone>+34 955 012 638</phone>
      <email>lluissemperebordes@gmail.com</email>
    </contact>
    <investigator>
      <last_name>María Jesús Sánchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Díez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arrate Placer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Niño Jesus</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>José Antonio Alonso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Manuel Quintana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nataly Cancelliere, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paula de la Torre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Navarro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carmen Campos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://biotrabis.com/</url>
    <description>Biotrabis study website</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Virgen Macarena</investigator_affiliation>
    <investigator_full_name>Joan Montaner Villalonga</investigator_full_name>
    <investigator_title>Joan Montaner, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Brain Concussion</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

